Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology
- PMID: 9808077
- DOI: 10.1177/0269881198012003021
Selective serotonin reuptake inhibitors in affective disorders--I. Basic pharmacology
Abstract
The selective serotonin reuptake inhibitors (SSRIs), citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline, are the result of rational research to find drugs that were as effective as the tricyclic antidepressants but with fewer safety and tolerability problems. The SSRIs selectively and powerfully inhibit serotonin reuptake and result in a potentiation of serotonergic neurotransmission. The property of potent serotonin reuptake appears to give a broad spectrum of therapeutic activity in depression, anxiety, obsessional and impulse control disorders. However, despite the sharing of the same principal mechanism of action, SSRIs are structurally diverse with clear variations in their pharmacodynamic and pharmacokinetic profiles. The potency for serotonin reuptake inhibition varies amongst this group, as does the selectivity for serotonin relative to noradrenaline and dopamine reuptake inhibition. The relative potency of sertraline for dopamine reuptake inhibition differentiates it pharmacologically from other SSRIs. Affinity for neuroreceptors, such as sigma1, muscarinic and 5-HT2c, also differs widely. Furthermore, the inhibition of nitric oxide synthetase by paroxetine, and possibly other SSRIs, may have significant pharmacodynamic effects. Citalopram and fluoxetine are racemic mixtures of different chiral forms that possess varying pharmacokinetic and pharmacological profiles. Fluoxetine has a long acting and pharmacologically active metabolite. There are important clinical differences among the SSRIs in their pharmacokinetic characteristics. These include differences in their half-lives, linear versus non-linear pharmacokinetics, effect of age on their clearance and their potential to inhibit drug metabolising cytochrome P450 (CYP) isoenzymes. These pharmacological and pharmacokinetic differences underly the increasingly apparent important clinical differences amongst the SSRIs.
Similar articles
-
Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism.Clin Pharmacokinet. 1997;32 Suppl 1:1-21. doi: 10.2165/00003088-199700321-00003. Clin Pharmacokinet. 1997. PMID: 9068931 Review.
-
Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors.Clin Pharmacokinet. 1996 Dec;31(6):444-69. doi: 10.2165/00003088-199631060-00004. Clin Pharmacokinet. 1996. PMID: 8968657 Review.
-
Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding.Cell Mol Neurobiol. 1999 Aug;19(4):467-89. doi: 10.1023/a:1006986824213. Cell Mol Neurobiol. 1999. PMID: 10379421 Review.
-
Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.Int J Clin Pract. 2005 Dec;59(12):1428-34. doi: 10.1111/j.1368-5031.2005.00681.x. Int J Clin Pract. 2005. PMID: 16351675 Review.
-
Clinical pharmacokinetics of selective serotonin reuptake inhibitors.Clin Pharmacokinet. 1993 Mar;24(3):203-20. doi: 10.2165/00003088-199324030-00003. Clin Pharmacokinet. 1993. PMID: 8384945 Review.
Cited by
-
Unlocking the Potential of High-Quality Dopamine Transporter Pharmacological Data: Advancing Robust Machine Learning-Based QSAR Modeling.bioRxiv [Preprint]. 2024 Mar 11:2024.03.06.583803. doi: 10.1101/2024.03.06.583803. bioRxiv. 2024. PMID: 38558976 Free PMC article. Preprint.
-
The pathobiology of depression in Huntington's disease: an unresolved puzzle.J Neural Transm (Vienna). 2024 Feb 13. doi: 10.1007/s00702-024-02750-w. Online ahead of print. J Neural Transm (Vienna). 2024. PMID: 38349403 Review.
-
Developmental exposure to sertraline impaired zebrafish behavioral and neurochemical profiles.Front Physiol. 2022 Nov 18;13:1040598. doi: 10.3389/fphys.2022.1040598. eCollection 2022. Front Physiol. 2022. PMID: 36467683 Free PMC article.
-
Current and Possible Future Therapeutic Options for Huntington's Disease.J Cent Nerv Syst Dis. 2022 May 21;14:11795735221092517. doi: 10.1177/11795735221092517. eCollection 2022. J Cent Nerv Syst Dis. 2022. PMID: 35615642 Free PMC article. Review.
-
Associations Between Prenatal Exposure to Serotonergic Medications and Biobehavioral Stress Regulation: Protocol for a Systematic Review and Meta-analysis.JMIR Res Protoc. 2022 Mar 28;11(3):e33363. doi: 10.2196/33363. JMIR Res Protoc. 2022. PMID: 35343913 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical